Startup secures $5.

Announced merger aims to foster collaboration an

New research shows that stochastic variation alo

Delivering siRNA therapies to the kidney could p

A novel peptide could provide a more targeted ap

Scott Fulton explores how emerging technologies

Oura Ring 4 tracks new signals to improve accura

The Cat Health Company aims to develop cutting-e

Combining synthetic biology and AI, company seek

New study highlights potential treatment for ext

Company is developing dual agonist and tri-agoni

The network state concept could give longevity b

Frontier Bio develops complex lab-grown lung tis

CheekAge uses easy-to-collect cheek cells to acc

Diagnostics firm lands more than $20 million in

New research introduces a precise method of reve

Company’s AI-powered technology detects cardio

Fast-moving startup is taking a multidisciplinar

Company commercializes human lactoferrin product

Setting sail for blue zones – the exclusive co

Global experts gather at 2024 Roundtable of Long

Chi Longevity clinic to open new location at Fou

New company exits stealth backed by innovative s

BioAge aims to raise $198 million in initial pub

Our first half of 2024 report on longevity inves

Combination with NLRP3 inhibitor achieves 50% gr

As Longevity Investors Conference gets underway,

Startup pet longevity company focused on cats cl

After scrapping initial SPAC deal, Longevity Bio

GC Therapeutics’ plug-and-play stem cell progr

Global industry leaders converge in Singapore to

As the International Longevity Summit approaches

Phase 2 study data indicates ‘dose-dependent i

Company aims to inhibit SARM1 enzyme to prevent

Designed to protect key retinal cells, company’s Fas inhibitor drugs aim to prevent vision loss in a range of conditions. With the world buzzing about Neuralink’s latest project to restore sight to the blind, others take the view that prevention is better than cure. To that end, US biopharma ONL Therapeutics has completed an oversubscribed $65 million Series D financing round to advance the clinical development of its novel therapeutics aimed at protecting retinal cells. ONL’s approach is focused on inhibiting Fas-mediated cell death, a critical mechanism in many ophthalmic diseases. Fas signaling plays a dual role in activating cell death and regulating immune responses, which can further damage retinal cells. The company’s lead compound, ONL1204, is a first-in-class small molecule Fas inhibitor, designed to protect key retinal cells, including photoreceptors, from Fas-induced cell death, a primary cause of vision loss in a range of conditions. By targeting Fas signaling, ONL aims to address both the direct and inflammatory pathways leading to cell death, potentially offering a broad therapeutic benefit across a range of retinal diseases. The funding will be used to initiate a global Phase 2 study in patients suffering from geographic atrophy (GA) linked to dry age-related macular degeneration (AMD).…

Collaboration aims to empower health practitione

Coya Therapeutics is pioneering multi-pathway th

Elon Musk claims that experimental ‘Blindsight

Boosting cellular regeneration, reducing inflamm

Chai Discovery emerges with $30m in funding and

A new study considers epigenetic aging from a si

DoD-backed startup targets clinical trials of bi

Preventive health company appoints former Amazon

Ahead of Longevity Investors Conference, Matt Py

Chopra Foundation CEO on why longevity needs to

Company integrates generative biology, chemistry

Ahead of Longevity Investors Conference, Andrea

Research highlights novel gene therapy delivery

Project aims to scale production of induced plur

Longevity company builder Maximon spawns new ven